Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SIM0718 in adults and adolescents with moderate-to-severe asthma
CTR20242195Phase 3Active
- Sponsor
- 苏州康乃德生物医药有限公司
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rademikibart in asthma, sponsored by 苏州康乃德生物医药有限公司. Started Jul 2024; status: active.
02
Drugs
rademikibart
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20242195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242195.